1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
1-year Clinical Outcomes After Intravenous Rt-PA for Chinese AIS Patients
Sponsor: Boehringer Ingelheim
This observational or N/A phase trial investigates Stroke and is currently completed. Boehringer Ingelheim leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Nov 2024 — Present [monthly]
Completed
-
Sep 2024 — Nov 2024 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Dec 2022 — Jan 2023 [monthly]
Active Not Recruiting
▶ Show 4 earlier versions
-
Nov 2022 — Dec 2022 [monthly]
Active Not Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting
Status: Not Yet Recruiting → Active Not Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Not Yet Recruiting
First recorded
Apr 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .